BNB Plus Corp. Completes Historic $1.2 Million LineaDNATM Order

AI Briefing

• – BNB Plus Corp.'s biopharmaceutical subsidiary LineaRx completes $1.2M order with zero batch failures, demonstrating technical excellence and manufacturing reliability.
• – Order was produced at historically higher margins.
• – Shipment completed in early May 2026.